Trastuzumab and Hyaluronidase
Medically reviewed by Drugs.com. Last updated on Jan 23, 2019.
(tras TOOZ ue mab & HYE al ure ON i dase)
- Herceptin Hylecta
- Hyaluronidase and Trastuzumab
- Trastuzumab and Hyaluronidase-oysk
- Trastuzumab and Recombinant Human Hyaluronidase PH20
- Trastuzumab and rHuPH20
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Subcutaneous [preservative free]:
Herceptin Hylecta: Trastuzumab 600 mg and hyaluronidase 10,000 units per 5 mL (5 mL)
Brand Names: U.S.
- Herceptin Hylecta
- Antineoplastic Agent, Anti-HER2
- Antineoplastic Agent, Monoclonal Antibody
Trastuzumab is a monoclonal antibody which binds to the extracellular domain of the human epidermal growth factor receptor 2 protein (HER-2); it mediates antibody-dependent cellular cytotoxicity by inhibiting proliferation of cells which overexpress HER-2 protein.
Hyaluronidase increases the dispersion and absorption rate of subcutaneous trastuzumab-containing products by increasing permeability of subcutaneous tissue through temporary depolymerization of hyaluronan; at the recommended doses, hyaluronidase acts transiently and locally; permeability of the subcutaneous tissue is restored within 24 to 48 hours.
Trastuzumab: SubQ: 2.9 L
Trastuzumab: SubQ: In most patients, trastuzumab is estimated to reach concentrations of <1 mcg/mL by 7 months following the last trastuzumab/hyaluronidase dose.
Clearance: Linear: Trastuzumab: SubQ: 0.11 L/day
Time to Peak
Trastuzumab: SubQ: ~3 days (Jackisch 2015)
Special Populations Note
Body weight: While not clinically relevant, body weight demonstrated a statistically significant influence on pharmacokinetics. The mean steady state AUC of trastuzumab was ~80% higher after trastuzumab/hyaluronidase (compared to IV trastuzumab) in patients <51 kg. The AUC was 20% lower after trastuzumab/hyaluronidase (compared to IV trastuzumab) in patients >90 kg.
Use: Labeled Indications
Breast cancer, adjuvant treatment: Adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature) in adults with breast cancer, as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; as part of a treatment regimen with docetaxel and carboplatin; as a single agent following multi-modality anthracycline-based therapy.
Breast cancer, metastatic: First-line treatment of HER2-overexpressing metastatic breast cancer (in combination with paclitaxel) in adults; single agent treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease.
Limitations of use: Select patients for trastuzumab treatment based on an approved companion diagnostic test for tumor specimen for HER2 overexpression or HER2 gene amplification.
There are no contraindications listed in the manufacturer's labeling.
Note: Do not substitute trastuzumab/hyaluronidase with IV trastuzumab products (eg, conventional trastuzumab or ado-trastuzumab emtansine). No loading dose is required.
Breast cancer, adjuvant treatment, HER2+: SubQ: Trastuzumab 600 mg/hyaluronidase 10,000 units once every 3 weeks for 52 weeks or until disease progression or unacceptable toxicity, whichever occurs first. Administer in combination with doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; or in combination with docetaxel and carboplatin; or as a single agent following multi-modality anthracycline based therapy.
Breast cancer, metastatic, HER2+: SubQ: Trastuzumab 600 mg/hyaluronidase 10,000 units once every 3 weeks (in combination with paclitaxel or as a single agent following one or more chemotherapy regimens for metastatic disease) until disease progression or unacceptable toxicity.
Missed doses: If one dose is missed, administer the missed dose as soon as possible. The interval between subsequent trastuzumab/hyaluronidase doses should not be <3 weeks.
Refer to adult dosing.
Dosing: Adjustment for Toxicity
≥16% absolute left ventricular ejection fraction (LVEF) decrease from pretreatment values or LVEF below institutional limits of normal and ≥10% absolute decrease in LVEF from pretreatment values: Withhold trastuzumab/hyaluronidase dosing for at least 4 weeks. If LVEF returns to normal limits and the absolute decrease from baseline is ≤15% within 4 to 8 weeks, may resume trastuzumab/hyaluronidase.
Persistent (>8 weeks) LVEF decline or if trastuzumab/hyaluronidase dosing is withheld on >3 occasions for cardiomyopathy: Permanently discontinue trastuzumab/hyaluronidase.
Grade 1 or 2 hypersensitivity (reversible): Consider premedication with an analgesic, antipyretic, or an antihistamine prior to subsequent trastuzumab/hyaluronidase doses.
Anaphylaxis or severe hypersensitivity reactions: Permanently discontinue trastuzumab/hyaluronidase.
Using a transfer needle, withdraw solution from vial into a syringe; replace transfer needle with a syringe closing cap. To avoid clogging the needle, attach the needle to the syringe immediately prior to administration and adjust volume to 5 mL. Trastuzumab/hyaluronidase is compatible with syringes made with polypropylene and polycarbonate and with stainless steel transfer and injection needles.
SubQ: Administer subcutaneously over 2 to 5 minutes. For subcutaneous use only. Doses should be administered by a health care professional. Alternate the injection site between the left and right thigh. Administer new injections on healthy skin at least 2.5 cm from the previous site; do not administer into areas where the skin is red, bruised, tender, or hard, or areas where there are moles or scars. Do not administer other subcutaneous medications at the same sites as trastuzumab/hyaluronidase. To avoid clogging the needle, attach the injection needle to the syringe immediately prior to administration followed by volume adjustment to 5 mL.
Check label to ensure appropriate product is being administered; trastuzumab/hyaluronidase, conventional trastuzumab products, and ado-trastuzumab emtansine are different products and are NOT interchangeable).
Store intact vials at 2°C to 8°C (36°F to 46°F); do not freeze. Store in the original carton to protect from light. Do not shake. Once vial is removed from the refrigerator, trastuzumab/hyaluronidase must be administered within 4 hours and should not be kept above 30°C (86°F). If syringe prepared for administration is not used immediately, store the syringe refrigerated at 2°C to 8°C (36°F to 46°F) (do not freeze) for up to 24 hours and subsequently at room temperature at 20°C to 25°C (68°F to 77°F) for up to 4 hours. Protect from light. Do not shake.
Alpha-/Beta-Agonists: Hyaluronidase may enhance the vasoconstricting effect of Alpha-/Beta-Agonists. Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of alpha-/beta-agonists. Use of hyaluronidase for other purposes in patients receiving alpha-/beta-agonists may be considered as clinically indicated. Exceptions: EPINEPHrine (Nasal); EPINEPHrine (Oral Inhalation); Isometheptene; Pseudoephedrine. Consider therapy modification
Anthracyclines: Trastuzumab may enhance the cardiotoxic effect of Anthracyclines. Management: When possible, patients treated with trastuzumab should avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab. Monitor closely for cardiac dysfunction in patients receiving anthracyclines with trastuzumab. Consider therapy modification
Antihistamines: May diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required. Consider therapy modification
Corticosteroids: May diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required. Exceptions: Beclomethasone (Nasal); Budesonide (Nasal); Ciclesonide (Nasal); Desonide; Dexamethasone (Ophthalmic); Difluprednate; Flunisolide (Nasal); Fluocinolone (Ophthalmic); Fluticasone (Nasal); Hydrocortisone (Ophthalmic); Loteprednol; Mometasone (Nasal); PrednisoLONE (Ophthalmic); Triamcinolone (Nasal); Triamcinolone (Ophthalmic). Consider therapy modification
DOPamine: Hyaluronidase may enhance the adverse/toxic effect of DOPamine. Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of dopamine. Use of hyaluronidase for other purposes in patients receiving dopamine may be considered as clinically indicated. Consider therapy modification
Estrogen Derivatives: May diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving estrogens (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required. Consider therapy modification
Immunosuppressants: Trastuzumab may enhance the neutropenic effect of Immunosuppressants. Exceptions: Cytarabine (Liposomal). Monitor therapy
Local Anesthetics: Hyaluronidase may enhance the adverse/toxic effect of Local Anesthetics. Exceptions: Benzocaine; Benzydamine; Cocaine (Topical); Dibucaine; Dyclonine; Ethyl Chloride; Hexylresorcinol; Lidocaine (Ophthalmic); Lidocaine (Topical); Pramoxine; Proparacaine; Tetracaine (Ophthalmic); Tetracaine (Topical). Monitor therapy
PACLitaxel (Conventional): Trastuzumab may decrease the serum concentration of PACLitaxel (Conventional). PACLitaxel (Conventional) may increase the serum concentration of Trastuzumab. Monitor therapy
Phenylephrine (Systemic): Hyaluronidase may enhance the vasoconstricting effect of Phenylephrine (Systemic). Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of phenylephrine. Use of hyaluronidase for other purposes in patients receiving phenylephrine may be considered as clinically indicated. Avoid combination
Salicylates: May diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving salicylates (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required. Consider therapy modification
Note: Incidences reported may be with concomitant chemotherapy.
Cardiovascular: Edema (12% to 14%), flushing (12% to 14%)
Central nervous system: Fatigue (21% to 46%), peripheral neuropathy (14% to 20%; grade ≥3: <1%), headache (13% to 17%), peripheral sensory neuropathy (11%)
Dermatologic: Alopecia (9% to 63%), skin rash (10% to 26%), nail disease (10% to 14%)
Gastrointestinal: Nausea (15% to 49%), diarrhea (21% to 34%), vomiting (7% to 23%), stomatitis (6% to 21%; grade ≥3: <1%), decreased appetite (20%), abdominal pain (10% to 14%), constipation (9% to 14%), dyspepsia (11%)
Hematologic & oncologic: Neutropenia (6% to 44%; grade ≥3: 4% to 30%), anemia (8% to 12%; grade ≥3: <1%), leukopenia (1% to 11%; grade ≥3: 1% to 5%)
Immunologic: Antibody development (16% to 21%; neutralizing: 6%)
Local: Injection site reaction (10% to 20%), incisional pain (11%)
Neuromuscular & skeletal: Asthenia (12% to 25%), arthralgia (18% to 21%), myalgia (14% to 21%), limb pain (10% to 11%), back pain (8% to 11%)
Respiratory: Upper respiratory tract infection (10% to 24%), cough (11% to 12%), dyspnea (7% to 11%)
Miscellaneous: Radiation injury (skin: 14%), fever (11% to 13%)
1% to 10%:
Cardiovascular: Hypertension (2% to 8%), cardiac arrhythmia (5%), reduced ejection fraction (5%), left ventricular dysfunction (3%), palpitations (2%), tachycardia (2%), cardiac failure (1%)
Central nervous system: Dizziness (6% to 10%), pain (5% to 8%), insomnia (7%), paresthesia (6%)
Dermatologic: Skin discoloration (9%), erythema of skin (7% to 9%), pruritus (6% to 9%), cellulitis (grade ≥3: 1%)
Endocrine & metabolic: Hot flash (10%), menstrual disease (grade ≥3%: 2%), amenorrhea (grade ≥3: 1%)
Gastrointestinal: Dysgeusia (10%)
Genitourinary: Urinary tract infection (6% to 4%)
Hematologic & oncologic: Febrile neutropenia (2% to 6%; grade ≥3: 2% to 6%), granulocytopenia (grade ≥3: 1%)
Hepatic: Abnormal hepatic function tests (6%)
Hypersensitivity: Hypersensitivity reaction (7% to 9%), anaphylaxis (4%)
Infection: Viral infection (5%)
Local: Erythema at injection site (7%), pain at injection site (6%)
Neuromuscular & skeletal: Musculoskeletal pain (7% to 8%), ostealgia (6%)
Respiratory: Epistaxis (6%), nasal discomfort (≤6%), rhinitis (≤6%)
<1%, postmarketing, and/or case reports: Acute respiratory distress syndrome, cardiomyopathy, decreased left ventricular ejection fraction, discomfort at injection site, drug-induced hypersensitivity reaction, hypoxia, interstitial pneumonitis, noncardiogenic pulmonary edema, pleural effusion, pulmonary fibrosis, pulmonary infiltrates, pulmonary toxicity, respiratory insufficiency
ALERT: U.S. Boxed WarningCardiomyopathy:
Trastuzumab and hyaluronidase administration can result in sub-clinical and clinical cardiac failure. The incidence and severity was highest in patients receiving trastuzumab and hyaluronidase with anthracycline-containing chemotherapy regimens. Evaluate left ventricular function in all patients prior to and during treatment with trastuzumab and hyaluronidase. Discontinue trastuzumab and hyaluronidase treatment in patients receiving adjuvant therapy and withhold trastuzumab and hyaluronidase in patients with metastatic disease for clinically significant decrease in left ventricular function.Pulmonary toxicity:
Trastuzumab and hyaluronidase administration can result in serious and fatal pulmonary toxicity. Symptoms usually occur during or within 24 hours of trastuzumab and hyaluronidase administration. Discontinue trastuzumab and hyaluronidase for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome. Monitor patients until symptoms completely resolve.Embryo-fetal toxicity:
Exposure to trastuzumab and hyaluronidase during pregnancy can result in oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Advise patients of these risks and the need for effective contraception.
Concerns related to adverse effects:
• Cardiomyopathy: [US Boxed Warning]: Trastuzumab/hyaluronidase administration can result in subclinical and clinical cardiac failure. The incidence and severity was highest in patients receiving trastuzumab/hyaluronidase with anthracycline-containing chemotherapy regimens. Evaluate left ventricular function in all patients prior to and during treatment with trastuzumab/hyaluronidase. Discontinue trastuzumab/hyaluronidase treatment in patients receiving adjuvant therapy and withhold trastuzumab/hyaluronidase in patients with metastatic disease for clinically significant decrease in left ventricular function. Trastuzumab/hyaluronidase may cause left ventricular cardiac dysfunction, arrhythmias, hypertension, disabling cardiac failure, cardiomyopathy, and cardiac death. Trastuzumab/hyaluronidase may also result in an asymptomatic decline in left ventricular ejection fraction (LVEF). Other cardiac adverse effects associated with trastuzumab/hyaluronidase include tachycardia, palpitations, and heart failure. Among patients receiving trastuzumab (as a single agent or in combination with chemotherapy), there is a 4- to 6-fold increase in the incidence of symptomatic myocardial dysfunction, compared to patients not receiving trastuzumab. The highest absolute incidence occurs when trastuzumab is administered with an anthracycline. The incidence of symptomatic myocardial dysfunction for trastuzumab/hyaluronidase and intravenous trastuzumab was similar in clinical trials. Withhold trastuzumab/hyaluronidase for ≥16% absolute decrease in LVEF from pretreatment values or an LVEF value below institutional limits of normal and ≥10% absolute decrease in LVEF (from pretreatment values). The safety of continuing or resuming trastuzumab/hyaluronidase with trastuzumab-induced left ventricular cardiac dysfunction has not been studied. Patients who receive anthracycline after stopping trastuzumab/hyaluronidase may also be at increased risk of cardiac dysfunction. Conduct thorough cardiac assessment, including history, physical examination, and LVEF assessment (by echocardiogram or MUGA scan). LVEF should be assessed at baseline (immediately prior to trastuzumab/hyaluronidase initiation), every 3 months during and upon completion of trastuzumab/hyaluronidase therapy, every 4 weeks if trastuzumab/hyaluronidase is withheld for significant left ventricular cardiac dysfunction, and every 6 months for at least 2 years following completion of trastuzumab/hyaluronidase when used as a component of adjuvant therapy.
ASCO has developed guidelines for prevention and monitoring of cardiac dysfunction in adult survivors of cancer (ASCO [Armenian 2017]). According to the guidelines, the risk of cardiac dysfunction related to trastuzumab is increased with the following:
- Trastuzumab alone AND any of the following risk factors: Multiple cardiovascular risk factors (≥2 risk factors), including smoking, hypertension, diabetes, dyslipidemia, and obesity (during or after completion of therapy), or older age (≥60 years of age) at cancer treatment, or compromised cardiac function (eg, borderline low LVEF [50% to 55%], history of MI, moderate or higher valvular heart disease) before or during treatment.
- Treatment with lower-dose anthracycline (eg, doxorubicin <250 mg/m2, epirubicin <600 mg/m2) followed by trastuzumab (sequential therapy)
The ASCO guidelines recommend a comprehensive assessment in patients with cancer that includes a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking. An echocardiogram should be obtained prior to initiating potentially cardiotoxic therapies. Modifiable risk factors (smoking, hypertension, diabetes, dyslipidemia, obesity) should be actively managed before initiating potentially cardiotoxic therapies. In patients who develop signs/symptoms of cardiac dysfunction during therapy, in addition to the above LVEF monitoring recommendations, an echocardiogram is recommended for diagnostic workup; if echocardiogram is not available or feasible, a cardiac MRI (preferred) or MUGA scan may be utilized. Serum cardiac biomarkers are recommended, along with referral to a cardiologist if indicated. Routine echocardiographic surveillance may be utilized in patients with metastatic breast cancer receiving trastuzumab indefinitely.
• Hypersensitivity: Severe hypersensitivity reactions, including anaphylaxis, have been reported with trastuzumab/hyaluronidase. Patients with dyspnea at rest due to complications of advanced malignancy and/or comorbidities may be at increased risk of a severe or fatal adverse reaction. Grades 3 or 4 reactions have occurred (rare); permanent discontinuation due to hypersensitivity or anaphylaxis was required in a small number of patients. Serious and fatal reactions have been reported following treatment with IV trastuzumab products. Monitor for systemic hypersensitivity reactions, particularly with the initial dose. Permanently discontinue trastuzumab/hyaluronidase in patients who experience anaphylaxis or severe hypersensitivity reactions. Medications to treat anaphylaxis or hypersensitivity and emergency equipment should be available for immediate use. Consider premedication with an analgesic, antipyretic, or an antihistamine prior to subsequent trastuzumab/hyaluronidase doses in patients who experienced a reversible grade 1 or 2 hypersensitivity reaction.
• Pulmonary toxicity: [US Boxed Warning]: Trastuzumab/hyaluronidase administration can result in serious and fatal pulmonary toxicity. Symptoms usually occur during or within 24 hours of trastuzumab/hyaluronidase administration. Discontinue trastuzumab/hyaluronidase for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome. Monitor patients until symptoms completely resolve. Pulmonary toxicity includes dyspnea, interstitial pneumonitis, pulmonary infiltrates, pleural effusions, noncardiogenic pulmonary edema, pulmonary insufficiency and hypoxia, acute respiratory distress syndrome, and pulmonary fibrosis. Patients with symptomatic intrinsic lung disease or extensive pulmonary tumor involvement, resulting in dyspnea at rest, appear to have more severe pulmonary toxicity.
Concurrent drug therapy issues:
• Chemotherapy: Trastuzumab/hyaluronidase may increase the incidence of neutropenia when used in combination with myelosuppressive chemotherapy. The incidences of grades 3 and 4 neutropenia and febrile neutropenia were higher in patients receiving trastuzumab (compared to those who received chemotherapy alone).
• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.
• Pregnancy: [US Boxed Warning]: Exposure to trastuzumab/hyaluronidase during pregnancy can result in oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Advise patients of these risks and the need for effective contraception.
Dosage form specific issues:
• Do not interchange: Trastuzumab/hyaluronidase and conventional trastuzumab products or ado-trastuzumab emtansine are not interchangeable. Verify product label prior to reconstitution and administration to prevent medication errors. Dosing and treatment schedules differ between trastuzumab/hyaluronidase and conventional trastuzumab (Herceptin or trastuzumab biosimilars) or ado-trastuzumab emtansine (Kadcyla).
• HER2 expression: Establish human epidermal growth receptor 2 (HER2) status prior to treatment with an approved test, either HER2 protein overexpression by validated immunohistochemistry (IHC) assay or gene amplification by fluorescence in situ hybridization (FISH) assay. Tests appropriate for breast cancer should be used to assess HER2 status. Unreliable results may occur from improper assay performance, such as use of suboptimally fixed tissue, failure to utilize specified reagents or to include appropriate controls for assay validation, or incorrectly following specific assay instructions. Information regarding HER2 diagnostic testing may be found at http://www.fda.gov/CompanionDiagnostics.
Assess for human epidermal growth receptor 2 (HER2) overexpression and HER2 gene amplification by validated immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) methodology (pretherapy) specific for breast cancer. Pregnancy test (prior to treatment in women of reproductive potential). Assess left ventricular ejection fraction (LVEF) at baseline, every 3 months during treatment, upon therapy completion and if component of adjuvant therapy, every 6 months for at least 2 years; if treatment is withheld for significant LVEF dysfunction, monitor LVEF at 4-week intervals. Monitor for signs/symptoms of cardiomyopathy, hypersensitivity, and/or pulmonary toxicity.
Additional cardiovascular monitoring (ASCO [Armenian 2017]): Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking. In patients who develop signs/symptoms of cardiac dysfunction during therapy, an echocardiogram is recommended for diagnostic workup; if echocardiogram is not available or feasible, a cardiac MRI (preferred) or MUGA scan may be utilized; obtain serum cardiac biomarkers. Routine echocardiographic surveillance may be utilized in patients with metastatic breast cancer receiving trastuzumab indefinitely.
[US Boxed Warning]: Exposure to trastuzumab/hyaluronidase during pregnancy can result in oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Advise patients of these risks and the need for effective contraception. Adverse fetal events may occur with exposure during pregnancy or if exposure occurs within 7 months prior to conception.
Evaluate pregnancy status of females of reproductive potential prior to the initiation of therapy. Females of reproductive potential should use effective contraception during treatment and for at least 7 months after the last trastuzumab/hyaluronidase dose.
Also refer to individual monographs for additional information.
If exposure to trastuzumab/hyaluronidase occurs during pregnancy, or if a patient becomes pregnant during or within 7 months after treatment, report exposure to Genentech Adverse Events at 1-888-835-2555.
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience hair loss, lack of appetite, abdominal pain, change in taste, bone pain, joint pain, muscle pain, back pain, painful extremities, insomnia, mouth irritation, mouth sores, application site irritation, flushing, common cold symptoms, nail changes, skin discoloration, constipation, diarrhea, vomiting, or nausea. Have patient report immediately to prescriber signs of heart problems (cough or shortness of breath that is new or worse, swelling of the ankles or legs, abnormal heartbeat, weight gain of more than five pounds in 24 hours, dizziness, or passing out), signs of a severe pulmonary disorder (lung or breathing problems like difficulty breathing, shortness of breath, or a cough that is new or worse), signs of infection, severe headache, dizziness, passing out, vision changes, severe loss of strength and energy, burning or numbness feeling, depression, or signs of tumor lysis syndrome (tachycardia or abnormal heartbeat; any passing out; urinary retention; muscle weakness or cramps; nausea, vomiting, diarrhea or lack of appetite; or feeling sluggish) (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about hyaluronidase/trastuzumab
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- En Español
- Drug class: HER2 inhibitors
Other brands: Herceptin Hylecta